Exodus Point Capital Management, LP Glycomimetics Inc Transaction History

Exodus Point Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.55 - $3.49 $91,029 - $124,586	35,698 New	35,698 $107,000
Q2 2022 Aug 19, 2022	SELL	$0.54 - $1.15 $5,788 - $12,327	-10,720 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.0 - $1.58 $18,570 - $29,340	-18,570 Reduced 63.4%	10,720 $12,000
Q4 2021 Feb 11, 2022	BUY	$1.44 - $2.14 $9,875 - $14,676	6,858 Added 30.57%	29,290 $42,000
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $69,746 - $92,607	-38,748 Reduced 63.33%	22,432 $49,000
Q2 2021 Aug 16, 2021	BUY	$2.16 - $3.18 $95,111 - $140,024	44,033 Added 256.8%	61,180 $142,000
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $109,669 - $160,140	-37,948 Reduced 68.88%	17,147 $52,000
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $148,205 - $233,602	55,095 New	55,095 $207,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.